Navigation Links
Isis Highlights New Clinical Data on Anti-Cancer Antisense Drugs Featured at ASCO
Date:6/1/2009

cer. The new data confirmed that LY2181308 penetrates tumor tissue and reduces survivin mRNA and protein levels in tumor cells. In addition, Dr. Azeem Saleem, CRUK Senior Clinical Research Fellow, University of Manchester, presented results of a pharmacokinetic study of LY2181308 in patients with cancer. Using state-of-the-art imaging techniques to assess radiolabeled LY2181308 distribution in humans, Dr. Saleem reported that LY2181308 effectively penetrated tumor tissues. LY2181308 is currently being evaluated in two separate Phase 2 studies in patients with relapsed or refractory acute myeloid leukemia, and as a combination therapy in patients with hormone refractory prostate cancer.

Information in this press release is based upon data reported by Isis' drug development partners. Isis has not independently reviewed the clinical results described in this release, but has relied in its partner's statements entirely.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. New Fast and Precise Treatment Planning System Among Varian Medical Systems Highlights at American Brachytherapy Society 2009 Meeting
2. New survey highlights growing concern about risk of infection in cancer patients
3. New Book Highlights Human Cost of FDAs Failure to Investigate Medical Devices
4. New Survey Highlights Growing Concern About Risk of Infection in Cancer Patients and Emerging Antibiotic Resistance
5. FDAs Hydroxycut Recall Highlights the Need for Stem Cell Innovations ACTIVTox Human Liver Testing
6. Amgen Highlights Data to Be Presented at ASCO
7. Hospira Highlights Five Years of Progress and Future Opportunities at Its 2009 Annual Meeting of Shareholders
8. Dey, L.P. Highlights Perforomist(R) Inhalation Solution Data to Be Presented at the International Conference of the American Thoracic Society
9. Quality of life survey highlights need for holistic approach in elderly residential care
10. Saberi Release Highlights Case of Imprisoned Iranian AIDS Doctors
11. The Center for the Biology of Chronic Disease Highlights Anti-Cancer Activities of the Food Extracts Quercetin, EGCG, Glycyrrhizin, and Trans-Cinnamaldehyde
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 This ... private practices that have made outstanding and innovative ... support and progression of private practice physical therapy ... Physical Therapy Association. , On behalf of Performance ... owner and CEO of Performance accepted the award ...
(Date:12/17/2014)... A group of 127 scientists sent an “open ... to a recent statement by the center that was highly ... the efficacy of all brain exercises. , Signatories to the ... the center’s statement critical of brain exercise companies that overstate ... its case, in a document it had entitled “A Consensus ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 No matter ... been able to eradicate the head louse parasite—a common ... for parents. Each year between six and twelve million ... the Miami-based lice removal treatment company comes to the ... and environmentally friendly. With its track record of customer ...
(Date:12/17/2014)... 17, 2014 Project Veritas is releasing ... videos of MIT economist and Obamacare architect Jonathan Gruber ... O’Keefe conducted the interview, which is being distributed on ... was intentional mislabeling in the Affordable Care Act in ... A two-hundred-and-fifty billion dollar per year tax grab. , ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, 2014 (HealthDay ... phenomenon is when an illness that originated in animals jumps ... -- is not uncommon and keeps researchers on their toes ... make inroads into the human population. A new report ... in this case were guinea pigs. More specifically, they were ...
Breaking Medicine News(10 mins):Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3
... May 5 Today marks the launch of the ... network designed to focus exclusively on hospice and palliative ... their families worldwide need palliative care and support each ... cent actually receive it. The need for palliative care ...
... project entitled ,Good Practice in Traditional Chinese Medicine Research ... status of Traditional Chinese Medicine (TCM) research, identify problems ... as well as providing a forum for the exchange ... EU and China. , The three-year project ...
... Increase Hispanic Family Physicians in California LOS ANGELES and ... a $2 million grant to the David Geffen School ... , to expand its International Medical Graduate Program. The ... to serving California,s vulnerable communities and need to pass ...
... (NYSE: BSX ) is scheduled to participate ... Health Care Conference.Jim Tobin, President and Chief Executive Officer, ... beginning at approximately 9:20 a.m. E.T. Following the ... Officer will join Mr. Tobin in a question and ...
... With a Donation, TooNEW YORK, May 5 Honk if you,re ... their wheels trying to think of the perfect Mother,s Day gift, ... to make a unique gift -- one that may save lives ... You can use this traditional time of love and giving to ...
... wary of finding, however , , TUESDAY, May 5 (HealthDay ... the long-sought markers that could discern which tumors are ... , The currently hot debate about the value of ... the fact that the cancer is usually so slow-growing ...
Cached Medicine News:Health News:New International Alliance Launched to Address Urgent Needs of Palliative Care Patients Worldwide 2Health News:King's-led consortium wins €1 million EU funding for Chinese medicine research 2Health News:Kaiser Permanente Grant to Expand UCLA International Medical Center Graduate Program 2Health News:Kaiser Permanente Grant to Expand UCLA International Medical Center Graduate Program 3Health News:Kaiser Permanente Grant to Expand UCLA International Medical Center Graduate Program 4Health News:Biomarkers May Predict Aggressiveness of Prostate Cancer 2Health News:Biomarkers May Predict Aggressiveness of Prostate Cancer 3
(Date:12/19/2014)...  Decision Resources Group finds that the laparoscopic device ... will increase to a value of over $4.3 billion ... in the large direct energy device market. In particular, ... due to the advantages they offer and as new ... Decision Resources Group,s coverage of the U.S. laparoscopic device ...
(Date:12/19/2014)... KANSAS CITY, Kan. , Dec. 18, 2014 ... PETX ), a biopharmaceutical company focused on ... for companion animals, today announced positive results from ... company,s innovative drug for treating pain in dogs ... demonstrated improvements in pain assessment scores that were ...
(Date:12/17/2014)... 2014 Revenue and earnings above the ... and development In the past 2013/14 fiscal year ... percent to EUR 4.287 billion (last year: EUR 4.190 billion) ... to EUR 360 million. "Overall, 2013/14 was a successful fiscal ... , President and CEO of Carl Zeiss AG. "Thanks to ...
Breaking Medicine Technology:U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS Asserts its Position in Difficult Environment 2
... grants Company extension to address remaining questions on Marketing ... ... Pharma, Inc.,(Nasdaq: IDMI ) today announced that the Company ... (CHMP), the scientific,committee of the European Medicines Evaluation Agency (EMEA), ...
... for study, DENVER, Jan. 24 Regenerative ... a patient,s own stem cells to,regenerate bone and ... its,patent pending processes to treat tendon injuries., ... severe tennis,elbow, partial rotator cuff tears or Achilles ...
Cached Medicine Technology:IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival 2IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival 3IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival 4IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival 5New Non-Surgical Stem-Cell Procedure to Relieve Chronic Tendon Problems 2
... Medtronic's temporary pulse generators are meeting ... nurses, cardiologists, electrophysiologists and anesthesiologists. And, ... durability you expect from Medtronic.,Effective pacing ... Reverse battery polarity for quick battery ...
... temporary pacemaker is designed to be used ... atrial or ventricular or A-V sequential pacing. ... pacing modes are indicated for therapeutic, prophylactic, ... can be used to measure atrial or ...
... is a unique left ventricular assist device that ... is being used in a small group of ... part of an FDA-approved Feasibility Study. The patient ... external power source for minutes or hours. The ...
... This compact system provides an ideal ... in the laboratory, satellite lab and ... HEMA-TEK staining method with wedge-smear technology, ... complete standardization in a safe enclosed ...
Medicine Products: